HK1106227A1 - Crystalline form of a biphenyl compound - Google Patents

Crystalline form of a biphenyl compound

Info

Publication number: HK1106227A1
Authority: HK; Hong Kong
Prior art keywords: salt; crystalline form; biphenyl compound; hydroxy; biphenyl
Prior art date: 2004-08-16

Application number

HK07111424.6A

Other languages

English (en)

Inventor

Robert S Chao

Miroslav Rapta

Pierre-Jean Colson

Original Assignee

Theravance Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-16

Filing date

2007-10-23

Publication date

2008-03-07

2007-10-23 Application filed by Theravance Inc filed Critical Theravance Inc

2008-03-07 Publication of HK1106227A1 publication Critical patent/HK1106227A1/xx

Links

235000010290 biphenyl Nutrition 0.000 title 1
239000004305 biphenyl Substances 0.000 title 1
-1 biphenyl compound Chemical class 0.000 title 1
ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title 1
150000003839 salts Chemical class 0.000 abstract 4
208000019693 Lung disease Diseases 0.000 abstract 1
URWYQGVSPQJGGB-DHUJRADRSA-N [1-[3-[2-chloro-4-[[[(2r)-2-hydroxy-2-(8-hydroxy-2-oxo-1h-quinolin-5-yl)ethyl]amino]methyl]-5-methoxyanilino]-3-oxopropyl]piperidin-4-yl] n-(2-phenylphenyl)carbamate Chemical compound ClC=1C=C(CNC[C@H](O)C=2C=3C=CC(=O)NC=3C(O)=CC=2)C(OC)=CC=1NC(=O)CCN(CC1)CCC1OC(=O)NC1=CC=CC=C1C1=CC=CC=C1 URWYQGVSPQJGGB-DHUJRADRSA-N 0.000 abstract 1
AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical class OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

HK07111424.6A 2004-08-16 2007-10-23 Crystalline form of a biphenyl compound HK1106227A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US60180504P	2004-08-16	2004-08-16
PCT/US2005/029013 WO2006023454A1 (en)	2004-08-16	2005-08-15	Crystalline form of a biphenyl compound

Publications (1)

Publication Number	Publication Date
HK1106227A1 true HK1106227A1 (en)	2008-03-07

Family

ID=35687428

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK07111424.6A HK1106227A1 (en)	2004-08-16	2007-10-23	Crystalline form of a biphenyl compound

Country Status (26)

Country	Link
US (4)	US7521558B2 (xx)
EP (1)	EP1778672B1 (xx)
JP (2)	JP5032990B2 (xx)
KR (1)	KR101363352B1 (xx)
CN (1)	CN101006077B (xx)
AR (1)	AR051003A1 (xx)
AU (1)	AU2005277601B2 (xx)
BR (1)	BRPI0514413C1 (xx)
CA (1)	CA2575874C (xx)
DK (1)	DK1778672T3 (xx)
ES (1)	ES2400958T3 (xx)
HK (1)	HK1106227A1 (xx)
HR (1)	HRP20130192T1 (xx)
IL (1)	IL180853A (xx)
MA (1)	MA28825B1 (xx)
MX (1)	MX2007001688A (xx)
MY (1)	MY141224A (xx)
NO (1)	NO338770B1 (xx)
NZ (1)	NZ552796A (xx)
PL (1)	PL1778672T3 (xx)
PT (1)	PT1778672E (xx)
RU (1)	RU2381223C2 (xx)
SI (1)	SI1778672T1 (xx)
TW (1)	TWI374883B (xx)
WO (1)	WO2006023454A1 (xx)
ZA (1)	ZA200701057B (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6693202B1 (en) *	1999-02-16	2004-02-17	Theravance, Inc.	Muscarinic receptor antagonists
PE20040950A1 (es)	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TWI374883B (en) *	2004-08-16	2012-10-21	Theravance Inc	Crystalline form of a biphenyl compound
ES2265276B1 (es)	2005-05-20	2008-02-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US8429052B2 (en) *	2005-07-19	2013-04-23	Lincoln National Life Insurance Company	Method and system for providing employer-sponsored retirement plan
GB0602778D0 (en) *	2006-02-10	2006-03-22	Glaxo Group Ltd	Novel compound
TW200811105A (en) *	2006-04-25	2008-03-01	Theravance Inc	Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) *	2006-04-25	2008-03-01	Theravance Inc	Crystalline forms of a dimethylphenyl compound
RS20090137A (xx) *	2006-10-04	2010-06-30	Pfizer Limited	Sulfonamid derivati kao adrenergijski agonisti i muskarinski antagonisti
ES2302447B1 (es) *	2006-10-20	2009-06-12	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es)	2007-02-09	2009-09-11	Laboratorios Almirall S.A.	Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2320961B1 (es) *	2007-11-28	2010-03-17	Laboratorios Almirall, S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) *	2008-02-28	2009-09-02	Laboratorios Almirall, S.A.	Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
UY32297A (es)	2008-12-22	2010-05-31	Almirall Sa	Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en)	2009-03-12	2010-09-15	Almirall, S.A.	Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
CA2758353C (en) *	2009-04-14	2017-06-06	Dean David Edney	Process for the preparation of a biphenyl-2-ylcarbamic acid ester
SG175330A1 (en)	2009-04-23	2011-11-28	Theravance Inc	DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
AU2015234331B2 (en) *	2009-04-23	2017-08-03	Theravance Biopharma R&D Ip, Llc	Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2011081937A1 (en)	2009-12-15	2011-07-07	Gilead Sciences, Inc.	Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
EP2386555A1 (en)	2010-05-13	2011-11-16	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it)	2010-05-13	2011-11-14	De La Cruz Jose Antonio Freire	Piastra per la costruzione di carrelli per aeroplani
GB201009801D0 (en)	2010-06-11	2010-07-21	Astrazeneca Ab	Compounds 950
AR083115A1 (es)	2010-09-30	2013-01-30	Theravance Inc	Sales oxalato cristalinas de un compuesto diamida
EP2578570A1 (en)	2011-10-07	2013-04-10	Almirall, S.A.	Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
BR112014010551A2 (pt) *	2011-10-31	2017-05-02	Glaxosmithkline Ip Dev Ltd	composição adequada para a reconstituição em uma suspensão aquosa, pó para a combinação direta para o uso em composição farmacêutica, formulação farmacêutica de suspensão oral, e, suspensão oral
EP2592077A1 (en)	2011-11-11	2013-05-15	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en)	2011-11-11	2013-05-15	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2641900A1 (en)	2012-03-20	2013-09-25	Almirall, S.A.	Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EA201500651A1 (ru)	2012-12-18	2015-11-30	Альмираль, С.А.	НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛ- И ХИНУКЛИДИНИЛКАРБАМАТА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
TWI643853B (zh)	2013-02-27	2018-12-11	阿爾米雷爾有限公司	同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh)	2013-07-25	2015-05-16	Almirall Sa	含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh)	2013-07-25	2018-11-21	阿爾米雷爾有限公司	具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh)	2014-09-26	2016-05-16	阿爾米雷爾有限公司	具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TW201835041A (zh)	2017-02-17	2018-10-01	印度商托仁特生技有限公司	具β-腎上腺素促效劑及抗蕈毒活性化合物
WO2020047225A1 (en)	2018-08-30	2020-03-05	Theravance Biopharma R&D Ip, Llc	Methods for treating chronic obstructive pulmonary disease
US20240300919A1 (en) *	2021-02-19	2024-09-12	Gbr Laboratories Private Limited	A process for preparing batefenterol and intermediates thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS596860B2 (ja) *	1975-05-19	1984-02-15	オオツカセイヤクカブシキガイシヤ	５−〔（２−アルキルアミノ−１−ヒドロキシ）アルキル〕カルボスチリル誘導体の製造法
US6541669B1 (en)	1998-06-08	2003-04-01	Theravance, Inc.	β2-adrenergic receptor agonists
UA73543C2 (uk)	1999-12-07	2005-08-15	Тераванс, Інк.	Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
US7238709B2 (en) *	1999-12-07	2007-07-03	Theravance, Inc.	Therapeutic carbamates
US20030018019A1 (en)	2001-06-23	2003-01-23	Boehringer Ingelheim Pharma Kg	Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US6653323B2 (en) *	2001-11-13	2003-11-25	Theravance, Inc.	Aryl aniline β2 adrenergic receptor agonists
PE20040950A1 (es)	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2004356517A (ja)	2003-05-30	2004-12-16	Ebara Corp	基板洗浄装置及び基板洗浄方法
US20050025718A1 (en)	2003-07-31	2005-02-03	Boehringer Ingelheim International Gmbh	Medicaments for inhalation comprising an anticholinergic and a betamimetic
WO2005080375A1 (en)	2004-02-13	2005-09-01	Theravance, Inc.	Crystalline form of a biphenyl compound
TWI374883B (en) *	2004-08-16	2012-10-21	Theravance Inc	Crystalline form of a biphenyl compound

2005
- 2005-08-03 TW TW094126435A patent/TWI374883B/zh not_active IP Right Cessation
- 2005-08-08 AR ARP050103308A patent/AR051003A1/es active IP Right Grant
- 2005-08-15 MY MYPI20053814A patent/MY141224A/en unknown
- 2005-08-15 AU AU2005277601A patent/AU2005277601B2/en not_active Ceased
- 2005-08-15 WO PCT/US2005/029013 patent/WO2006023454A1/en active Application Filing
- 2005-08-15 JP JP2007527919A patent/JP5032990B2/ja not_active Expired - Fee Related
- 2005-08-15 US US11/204,065 patent/US7521558B2/en active Active
- 2005-08-15 MX MX2007001688A patent/MX2007001688A/es active IP Right Grant
- 2005-08-15 RU RU2007109598/04A patent/RU2381223C2/ru active
- 2005-08-15 NZ NZ552796A patent/NZ552796A/en not_active IP Right Cessation
- 2005-08-15 PL PL05803280T patent/PL1778672T3/pl unknown
- 2005-08-15 EP EP05803280A patent/EP1778672B1/en active Active
- 2005-08-15 PT PT58032806T patent/PT1778672E/pt unknown
- 2005-08-15 CN CN2005800281254A patent/CN101006077B/zh not_active Expired - Fee Related
- 2005-08-15 BR BRPI0514413A patent/BRPI0514413C1/pt not_active IP Right Cessation
- 2005-08-15 SI SI200531675T patent/SI1778672T1/sl unknown
- 2005-08-15 CA CA2575874A patent/CA2575874C/en active Active
- 2005-08-15 DK DK05803280.6T patent/DK1778672T3/da active
- 2005-08-15 KR KR1020077005834A patent/KR101363352B1/ko active IP Right Grant
- 2005-08-15 ES ES05803280T patent/ES2400958T3/es active Active
2007
- 2007-01-22 IL IL180853A patent/IL180853A/en active IP Right Grant
- 2007-02-05 ZA ZA200701057A patent/ZA200701057B/xx unknown
- 2007-02-23 MA MA29717A patent/MA28825B1/fr unknown
- 2007-03-09 NO NO20071307A patent/NO338770B1/no unknown
- 2007-10-23 HK HK07111424.6A patent/HK1106227A1/xx not_active IP Right Cessation
2009
- 2009-02-11 US US12/369,605 patent/US8101766B2/en not_active Expired - Fee Related
2011
- 2011-12-16 US US13/328,386 patent/US8476299B2/en active Active
2012
- 2012-03-22 JP JP2012065767A patent/JP2012121929A/ja not_active Withdrawn
2013
- 2013-03-05 HR HRP20130192TT patent/HRP20130192T1/hr unknown
- 2013-06-05 US US13/910,708 patent/US8754223B2/en active Active

Also Published As

Publication number	Publication date
JP5032990B2 (ja)	2012-09-26
US8101766B2 (en)	2012-01-24
CA2575874C (en)	2012-10-09
IL180853A (en)	2014-03-31
WO2006023454A1 (en)	2006-03-02
HRP20130192T1 (hr)	2013-04-30
US20090221638A1 (en)	2009-09-03
PT1778672E (pt)	2013-02-25
EP1778672B1 (en)	2012-12-19
AU2005277601B2 (en)	2011-10-27
MA28825B1 (fr)	2007-08-01
RU2007109598A (ru)	2008-09-27
RU2381223C2 (ru)	2010-02-10
ES2400958T3 (es)	2013-04-15
KR101363352B1 (ko)	2014-02-14
CN101006077A (zh)	2007-07-25
NO20071307L (no)	2007-04-11
BRPI0514413B1 (pt)	2019-04-16
US7521558B2 (en)	2009-04-21
KR20070057832A (ko)	2007-06-07
AR051003A1 (es)	2006-12-13
US20130289281A1 (en)	2013-10-31
NZ552796A (en)	2010-09-30
TWI374883B (en)	2012-10-21
JP2012121929A (ja)	2012-06-28
US20120283289A1 (en)	2012-11-08
IL180853A0 (en)	2007-07-04
US8476299B2 (en)	2013-07-02
ZA200701057B (en)	2008-08-27
MX2007001688A (es)	2007-04-23
US20060035931A1 (en)	2006-02-16
PL1778672T3 (pl)	2013-05-31
TW200613296A (en)	2006-05-01
CN101006077B (zh)	2012-04-25
EP1778672A1 (en)	2007-05-02
SI1778672T1 (sl)	2013-04-30
BRPI0514413C1 (pt)	2021-05-25
US8754223B2 (en)	2014-06-17
CA2575874A1 (en)	2006-03-02
MY141224A (en)	2010-03-31
AU2005277601A1 (en)	2006-03-02
BRPI0514413A (pt)	2008-06-10
JP2008513358A (ja)	2008-05-01
DK1778672T3 (da)	2013-03-25
NO338770B1 (no)	2016-10-17

Publication	Publication Date	Title
HK1106227A1 (en)	2008-03-07	Crystalline form of a biphenyl compound
TW200800948A (en)	2008-01-01	Novel compound
WO2007127297A3 (en)	2007-12-21	Crystalline forms of a dimethylphenyl compound
TW200714586A (en)	2007-04-16	Crystalline forms of a biphenyl compound
BRPI0906104A2 (pt)	2015-06-30	"derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade "terapeuticamente eficaz do derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido nuclêico peptídico,método de utilização do derivado de ácido nuclêico peptídico e composto"
NO20091620L (no)	2009-07-09	Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser
NO20080122L (no)	2008-01-08	Blanding av diisononylestere av 1,2syklodikarbonsyrer, fremgangsmate for dere fremstilling og anvendelse derav
MY174452A (en)	2020-04-19	Substituted piperidines that increase p53 activity and the uses thereof
WO2009155121A3 (en)	2010-02-18	Inhibitors of pi3 kinase
WO2008068615A8 (en)	2009-05-28	Crystalline forms of ( 3 s ) -3- [n- (n' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluoro phenoxy) -4-0x0penta noic acid
IL193771A (en)	2013-09-30	Preparations that act as protein inhibitors deliver cholesterol ester
EA201390481A1 (ru)	2013-08-30	Кристаллические оксалатные соли диамидного соединения
UA90130C2 (ru)	2010-04-12	Аморфный лерканидипина гидрохлорид и фармацевтическая композиция на его основе
WO2008050199A8 (en)	2009-04-16	Substituted phenylmethyl bicyclocarboxyamide compounds
SG10201407913UA (en)	2015-01-29	Crystalline freebase forms of a biphenyl compound
MX2011005090A (es)	2011-09-06	Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)feni l] piperidina.
PT2049480E (pt)	2013-12-16	Derivados de 2-arilindole como inibidores da mpges-i
EP1780207A3 (en)	2007-07-04	Crystalline esomeprazole strontium hydrate, method for preparing the same and pharmaceutical composition containing the same
WO2005123679A3 (en)	2006-03-02	Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2005123670A3 (en)	2006-02-09	Crystalline form of a substituted pyrrolidine compound
CY1112979T1 (el)	2016-04-13	Διαδικασια για την παρασκευη της ενωσης (s)-1-αλκυλ-2',6'-πιπεκολοξυλιδιδιου
CY1113646T1 (el)	2016-06-22	Κρυσταλλικη μορφη μιας ενωσης διφαινυλιου
SI1546083T1 (sl)	2010-11-30	Nove substituirane arilheksadienojske kisline in njihovi estri ki se lahko uporabljajo za zdravljenje in preprečevanje diabetesa dislipidemije in ateroskleroze farmacevtski sestavki ki jih vsebujejo in postopek njihove priprave
TH101961B (th)	2010-06-25	สารประกอบชนิดใหม่

Legal Events

Date	Code	Title	Description
2024-03-08	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20230815